Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD

By sjmartinez • February 13, 2025

Sciurba FC, Christenson SA, Rheault T, Bengtsson T, Rickard K, Barjaktarevic IZ. Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD. Chest. 2025 Feb;167(2):425-435. doi: 10.1016/j.chest.2024.07.168. Epub 2024 Aug 27. PMID: 39197510.

Tags: COPD, ensifentrine, exacerbation, patient-reported outcomes, Publications, Pulmonary, Critical Care & Sleep Medicine

Differences Among Veterans With Chronic Overlapping Pain Conditions and Other Chronic Pain: Baseline Results From the LAMP Pain Management Trial

Adamowicz JL, Grant A, Calvert C, Elchert D, Hadlandsmyth K, Driscoll MA, Taylor SL, Allen K, Taylor BC, Burgess DJ. Differences Among Veterans With Chronic[...]

Risk of Cutaneous T-cell Lymphoma in Patients with Autoimmune Diseases

Brumbaugh B, Westmeijer M, Thompson B, Holt A, Ebriani J, Sheng-Kai Ma K, Chen ST. Risk of Cutaneous T-cell Lymphoma in Patients with Autoimmune Diseases.[...]

SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis

Herrmann K, Walz J, MacLennan S, Briganti A, Cornford P, Czernin J, Eiber M, Fanti S, Fendler WP, Fizazi K, Gafita A, Gillessen S, Goffin[...]